Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521580

SCHEMBL1521580

SCHEMBL1521580

CCNc1nc(SC)ncc1C(=O)OCC

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.76
▸ SYK P43405 2/20 0.65
▸ MAPT P10636 5/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.61
▸ NFKB1 P19838 2/20 0.61
▸ NFKB2 Q00653 2/20 0.61
▸ RELA Q04206 2/20 0.61
▸ LMNA P02545 1/20 0.61
▸ FOS P01100 1/20 0.61
▸ JUN P05412 1/20 0.61
▸ MAPK1 P28482 2/20 0.60
▸ HTT P42858 1/20 0.60
▸ MEN1 O00255 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ TDP1 Q9NUW8 2/20 0.56
▸ POLB P06746 1/20 0.56
▸ HPGD P15428 2/20 0.52
▸ KDM4E B2RXH2 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.46
▸ NPC1 O15118 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2019145 0.90 ALDH1A1 (0.80) ALDH1A1SYKMAPTSMN1; SMN2NFKB1
SCHEMBL1521842 0.88 ALDH1A1 (0.70) ALDH1A1SYKMAPTSMN1; SMN2NFKB1
SCHEMBL29545771 0.88 ALDH1A1 (0.70) ALDH1A1SYKMAPTSMN1; SMN2NFKB1
SCHEMBL11163446 0.87 ALDH1A1 (0.69) ALDH1A1SYKMAPTSMN1; SMN2NFKB1
SCHEMBL30718919 0.87 ALDH1A1 (0.69) ALDH1A1SYKMAPTSMN1; SMN2NFKB1
SCHEMBL23141936 0.87 ALDH1A1 (0.69) ALDH1A1SYKMAPTSMN1; SMN2NFKB1
SCHEMBL28734766 0.87 ALDH1A1 (0.69) ALDH1A1SYKMAPTSMN1; SMN2NFKB1
SCHEMBL29508917 0.87 ALDH1A1 (0.69) ALDH1A1SYKMAPTSMN1; SMN2NFKB1
SCHEMBL1816274 0.86 SYK (0.69) ALDH1A1SYKMAPTSMN1; SMN2NFKB1
SCHEMBL3127909 0.86 ALDH1A1 (0.68) ALDH1A1SYKMAPTSMN1; SMN2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3733184-B1 PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ICAHN SCHOOL MED MOUNT SINAI (US) 2023-08-30 — — EP disclosed
EP-3733184-B1 PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ICAHN SCHOOL MED MOUNT SINAI (US) 2023-08-30 — — EP disclosed
CN-108864081-B FGFR4 inhibitor and preparation and application thereof 南京圣和药业股份有限公司 2021-11-23 — — CN disclosed
EP-3733184-A1 PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Icahn School of Medicine at Mount Sinai (US) 2020-11-04 — — EP disclosed
EP-3733184-A1 PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Icahn School of Medicine at Mount Sinai (US) 2020-11-04 — — EP disclosed
EP-2968331-B1 PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS ICAHN SCHOOL MED MOUNT SINAI (US) 2020-07-01 — — EP disclosed
EP-2968331-B1 PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS ICAHN SCHOOL MED MOUNT SINAI (US) 2020-07-01 — — EP disclosed
US-10000490-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2018-06-19 — — US disclosed
US-9815847-B2 Pyrimidine compounds as kinase inhibitors ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2017-11-14 — — US disclosed
US-9815847-B2 Pyrimidine compounds as kinase inhibitors ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2017-11-14 — — US disclosed
EP-1255755-A1 PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE WARNER-LAMBERT COMPANY (US) 2002-11-13 — — EP disclosed
WO-2002064594-A2 6-SUBSTITUTED PYRIDO-PYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 2002-08-22 — — WO disclosed
WO-2002012238-A2 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES WARNER-LAMBERT COMPANY (US) 2002-02-14 — — WO disclosed
WO-2002012237-A2 PROCESS FOR PREPARING 2-(4-PYRIDYL)AMINO-6-DIALKYLOXYPHENYL-PYRIDO[2,3-D]PYRIMIDIN-7-ONES WARNER-LAMBERT COMPANY (US) 2002-02-14 — — WO disclosed
WO-2001055148-A1 PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE WARNER-LAMBERT COMPANY (US) 2001-08-02 — — WO disclosed
EP-0964864-A2 PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 1999-12-22 — — EP disclosed
WO-1998033798-A2 PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION WARNER LAMBERT COMPANY (US) 1998-08-06 — — WO disclosed
US-5733914-A Pyrido 2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation WARNER-LAMBERT COMPANY (US) 1998-03-31 — — US disclosed
EP-0823908-A1 PYRIDO 2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 1998-02-18 — — EP disclosed
WO-1996034867-A1 PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 1996-11-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000490-B2 Inhibitors of the fibroblast growth factor receptor FGFR4, FGFR1, FGFR2 ALDH1A1 2337/4885SYK 637/4885MAPT 2978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.